These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27445490)

  • 61. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
    Ng VC; Johnson JJ; Cuellar S
    J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Mehta A; Tripathy D
    Breast; 2014 Feb; 23(1):2-9. PubMed ID: 24176518
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
    Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
    Clin Ther; 2016 Apr; 38(4):905-17. PubMed ID: 26947172
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer.
    Lv H; Yan M; Jiang Z
    Ther Adv Med Oncol; 2021; 13():17588359211013326. PubMed ID: 33995599
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.
    Yi Z; Ma F
    J Breast Cancer; 2017 Dec; 20(4):321-326. PubMed ID: 29285035
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.
    Beck JT
    Onco Targets Ther; 2015; 8():3629-38. PubMed ID: 26675495
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
    Niraula S; Ocana A
    Cancer Treat Rev; 2016 Nov; 50():168-174. PubMed ID: 27693931
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].
    Jerusalem G; Rorive A; Collignon J
    Rev Med Liege; 2014 Sep; 69(9):510-7. PubMed ID: 25796760
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PI3K/Akt/mTOR inhibitors in breast cancer.
    Lee JJ; Loh K; Yap YS
    Cancer Biol Med; 2015 Dec; 12(4):342-54. PubMed ID: 26779371
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials.
    El Sayed R; El Jamal L; El Iskandarani S; Kort J; Abdel Salam M; Assi H
    Front Oncol; 2019; 9():510. PubMed ID: 31281796
    [No Abstract]   [Full Text] [Related]  

  • 72. Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data.
    Armaghani AJ; Han HS
    Breast Cancer (Dove Med Press); 2020; 12():251-258. PubMed ID: 33239910
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients.
    Liang Y; Liu X; Yun Z; Li K; Li H
    Ther Adv Med Oncol; 2024; 16():17588359231220501. PubMed ID: 38188468
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    Fusco N; Malapelle U; Fassan M; Marchiò C; Buglioni S; Zupo S; Criscitiello C; Vigneri P; Dei Tos AP; Maiorano E; Viale G
    Front Oncol; 2021; 11():644737. PubMed ID: 33842357
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Everolimus in the Treatment of Metastatic Breast Cancer.
    Royce ME; Osman D
    Breast Cancer (Auckl); 2015; 9():73-9. PubMed ID: 26417203
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The PI3K Pathway: Background and Treatment Approaches.
    Lux MP; Fasching PA; Schrauder MG; Hein A; Jud SM; Rauh C; Beckmann MW
    Breast Care (Basel); 2016 Dec; 11(6):398-404. PubMed ID: 28228706
    [TBL] [Abstract][Full Text] [Related]  

  • 77. SABCS 2016: systemic therapy for metastatic breast cancer.
    Gampenrieder SP; Rinnerthaler G; Greil R
    Memo; 2017; 10(2):86-89. PubMed ID: 28725277
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New Agents for the Management of Advanced HER2-Positive Breast Cancer.
    Royce M; Herold K
    J Adv Pract Oncol; 2016 Apr; 7(3):295-298. PubMed ID: 29152392
    [No Abstract]   [Full Text] [Related]  

  • 79. Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
    Sun B; Ding L; Wu S; Meng X; Song S
    Onco Targets Ther; 2016; 9():3997-4003. PubMed ID: 27445490
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.